APA

Craxì L., Sacchini D., Refolo P., Minacori R., Daloiso V., Ricci G., Bruno R., Cammà C., Cicchetti A., Gasbarrini A. & Spagnolo A. G. (20161213). Prioritization of high-cost new drugs for HCV: making sustainability ethical. : European review for medical and pharmacological sciences.

Chicago

Craxì L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, Bruno R, Cammà C, Cicchetti A, Gasbarrini A and Spagnolo A G. 20161213. Prioritization of high-cost new drugs for HCV: making sustainability ethical. : European review for medical and pharmacological sciences.

Harvard

Craxì L., Sacchini D., Refolo P., Minacori R., Daloiso V., Ricci G., Bruno R., Cammà C., Cicchetti A., Gasbarrini A. and Spagnolo A. G. (20161213). Prioritization of high-cost new drugs for HCV: making sustainability ethical. : European review for medical and pharmacological sciences.

MLA

Craxì L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, Bruno R, Cammà C, Cicchetti A, Gasbarrini A and Spagnolo A G. Prioritization of high-cost new drugs for HCV: making sustainability ethical. : European review for medical and pharmacological sciences. 20161213.